If you have been reading about 内脏脂肪 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
He beat Andrey Rublev for the 17th title of his career and the fourth of the season, in 59 minutes, the shortest match in the tournament history. At the US Open, Zverev sought to claim his first major title following his run to the final the previous year. He reached the semifinals following wins over Jack Sock and Lloyd Harris. There, he lost to Novak Djokovic in five sets despite taking the first set, ending his career-high 16-match win streak stretching back to the Olympics. Zverev was seeded 3rd at the 2021 BNP Paribas Open, where he reached the quarterfinals. On the way, he defeated Jenson Brooksby, Andy Murray and Gaël Monfils. He lost to Taylor Fritz, despite having two match points. At the Erste Bank Open in Vienna, seeded second, he defeated Filip Krajinović and Alex de Minaur to reach the quarterfinals. The victory over De Minaur gave Zverev his 300th ATP tour match win. He then beat Félix Auger-Aliassime and Carlos Alcaraz to reach the final where he won his fifth title of the year and 18th overall, defeating Frances Tiafoe in straight sets. Zverev was the fourth seed at the 2021 Rolex Paris Masters. He received a bye into the second round, where he defeated Dušan Lajović. He defeated next sixteenth seed Grigor Dimitrov in the third round and sixth seed Casper Ruud in the quarterfinals. He lost in the semifinals to second seed Daniil Medvedev in straight sets. As a result of this run he equaled his singles career-high ranking of World No. 3 on 8 November 2021. For a fifth successive season, Zverev qualified for the 2021 ATP Finals in Turin, as the third seed.
In June 1659, the two armies met near the town of Konotop. One army comprised Cossacks, Tatars, and Poles, and the other was led by a top Muscovite military commander of the era, Prince Aleksey Trubetskoy. After terrible losses, Trubetskoy was forced to withdraw to the town of Putyvl on the other side of the border. The battle is regarded as one of the Zaporizhian Cossacks' most impressive victories. In 1659, Yurii Khmelnytsky was elected hetman of the Zaporizhian Host/Hetmanate, with the endorsement of Moscow and supported by common Cossacks unhappy with the conditions of the Union of Hadiach. In 1660, however, the hetman asked the Polish king for protection, leading to the period of Ukrainian history known as The Ruin.
==== Corrosion ==== In magnesium alloys, the presence of iron, nickel, copper, or cobalt strongly activates corrosion. In more than trace amounts, these metals precipitate as intermetallic compounds, and the precipitate locales function as active cathodic sites that reduce water, causing the loss of magnesium. Controlling the quantity of these metals improves corrosion resistance. Sufficient manganese overcomes the corrosive effects of iron. This requires precise control over composition, increasing costs. Adding a cathodic poison captures atomic hydrogen within the structure of a metal. This prevents the formation of free hydrogen gas, an essential factor of corrosive chemical processes. The addition of about one in three hundred parts arsenic reduces the corrosion rate of magnesium in a salt solution by a factor of nearly ten.
Sources: en.wikipedia.org
=== Antidotes === Andexxa (Andexanet alfa) from Portola Pharmaceuticals is a recombinant protein that is given intravenously. It works as an antidote to all direct and indirect FXa inhibitors. Andexxa acts as a decoy receptor for Xa inhibitors.
Oplophorus-luciferin 2-monooxygenase (EC 1.13.12.13), also known as Oplophorus luciferase (referred in this article as OpLuc) is a luciferase, an enzyme, from the deep-sea shrimp Oplophorus gracilirostris, belonging to a group of coelenterazine luciferases. Unlike other luciferases, it has a broader substrate specificity and can also bind to bisdeoxycoelenterazine efficiently. It was the third example of a luciferase (Other than Aequorea and Renilla) to be purified in lab. The systematic name of this enzyme class is Oplophorus-luciferin:oxygen 2-oxidoreductase (decarboxylating). This enzyme is also called Oplophorus luciferase.
reaction barrier The energy deficit that must be overcome in order for a particular chemical reaction to proceed. In transition state theory, the reaction barrier is interpreted as the difference between the zero-point energy of the activated complex formed in the reaction and that of the initial reactants. See also activation energy.
Sources: en.wikipedia.org
== Etymology == The word "aptamer" is a neologism coined by Andrew D. Ellington and Jack Szostak in their first publication on the topic. They did not provide a precise definition, stating "We have termed these individual RNA sequences 'aptamers', from the Latin aptus, to fit." The word itself, however, derives from the Greek word ἅπτω, to connect or fit (as used by Homer (c. 8th century BC)) and μέρος, a component of something larger.
=== Fibroblast growth factor === fibroblast growth factor (FGF-21) has been recently characterized as a potent metabolic regulator. Systemic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in genetically compromised diabetic rodents. FGF21 can function as a crucial regulator mediating beneficial metabolic effects of therapeutic agents such as metformin, glucagon/glucagonlike peptide1analogues, thiazolidinedione, sirtuin 1 activators, and lipoic acid. A study showed that when fibroblast growth factor-21 administered daily for 6 weeks to diabetic rhesus monkeys, it caused a dramatic decline in fasting plasma glucose, fructosamine, triglycerides, insulin and glucagon. In a significant point during the study, FGF-21 administration also led to significant improvements in lipoprotein profiles and a beneficial changes in the circulating levels of several cardiovascular risk markers. And the induction of a small but significant weight loss. These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases.
== Personal life and education == Anagani Satya Prasad (born January 10, 1972) was son of Anagani Ranga Rao. He was the relative of Anagani Bhagavantha Rao who was elected as MLA from Kuchinapudi constituency and served as minister in 1970–80s. Though his family was native of Cherukuapalli mandal, Satya Prasad childhood and education happened in Hyderabad city itself. His educational qualifications are as follows. He was unmarried as of June 2024 as per affidavit submitted for elections.
=== Prevention === Probiotic prophylaxis may prevent colonization and delay onset of Pseudomonas infection in an ICU setting. Immunoprophylaxis against Pseudomonas is being investigated. The risk of contracting P. aeruginosa can be reduced by avoiding pools, hot tubs, and other bodies of standing water; regularly disinfecting and/or replacing equipment that regularly encounters moisture (such as contact lens equipment and solutions); and washing one's hands often (which is protective against many other pathogens as well). However, even the best hygiene practices cannot totally protect an individual against P. aeruginosa, given how common the organism is in the environment.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.